Warts - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 85
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: W135F27F72BEN
Leaflet:

Download PDF Leaflet

Warts - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Warts - Pipeline Review, H2 2016’, provides an overview of the Warts pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Warts, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Warts and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Warts
  • The report reviews pipeline therapeutics for Warts by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Warts therapeutics and enlists all their major and minor projects
  • The report assesses Warts therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Warts
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Warts
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Warts Overview
Therapeutics Development
Pipeline Products for Warts - Overview
Warts - Therapeutics under Development by Companies
Warts - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Warts - Products under Development by Companies
Warts - Companies Involved in Therapeutics Development
3M DRUG DELIVERY SYSTEMS
Aclaris Therapeutics, Inc.
Agilvax, Inc.
Aviragen Therapeutics, Inc.
Biogenomics Limited
BioMAS Ltd.
Cytovation AS
Foamix Pharmaceuticals Ltd.
G&E Herbal Biotechnology Co., Ltd.
Laboratories Ojer Pharma S.L.
LEO Pharma A/S
Nielsen Biosciences, Inc.
Novan, Inc.
Novartis AG
Promius Pharma, LLC
RXi Pharmaceuticals Corporation
Tamir Biotechnology, Inc.
Verrica Pharmaceuticals Inc.
Zydus Cadila Healthcare Limited
Warts - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(cervical cancer + genital warts) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(digoxin + furosemide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
854-A - DRUG PROFILE
Product Description
Mechanism Of Action
R&D Progress
AS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AX-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTA-074 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Candida Albicans Antigen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CyPep-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DFD-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diphencyprone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FIT-039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrogen peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ingenol mebutate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LFX-453 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omiganan pentahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
povidone iodine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranpirnase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Warts - Dormant Projects
Warts - Discontinued Products
Warts - Product Development Milestones
Featured News & Press Releases
May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206
Dec 21, 2015: RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for Cutaneous Warts
Dec 07, 2015: Aclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Warts, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Warts - Pipeline by 3M Drug Delivery Systems, H2 2016
Warts - Pipeline by Aclaris Therapeutics, Inc., H2 2016
Warts - Pipeline by Agilvax, Inc., H2 2016
Warts - Pipeline by Aviragen Therapeutics, Inc., H2 2016
Warts - Pipeline by Biogenomics Limited, H2 2016
Warts - Pipeline by BioMAS Ltd., H2 2016
Warts - Pipeline by Cytovation AS, H2 2016
Warts - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
Warts - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016
Warts - Pipeline by Laboratories Ojer Pharma S.L., H2 2016
Warts - Pipeline by LEO Pharma A/S, H2 2016
Warts - Pipeline by Nielsen Biosciences, Inc., H2 2016
Warts - Pipeline by Novan, Inc., H2 2016
Warts - Pipeline by Novartis AG, H2 2016
Warts - Pipeline by Promius Pharma, LLC, H2 2016
Warts - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
Warts - Pipeline by Tamir Biotechnology, Inc., H2 2016
Warts - Pipeline by Verrica Pharmaceuticals Inc., H2 2016
Warts - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Warts - Dormant Projects, H2 2016
Warts - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Warts, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

3M Drug Delivery Systems
Aclaris Therapeutics, Inc.
Agilvax, Inc.
Aviragen Therapeutics, Inc.
Biogenomics Limited
BioMAS Ltd.
Cytovation AS
Foamix Pharmaceuticals Ltd.
G&E Herbal Biotechnology Co., Ltd.
Laboratories Ojer Pharma S.L.
LEO Pharma A/S
Nielsen Biosciences, Inc.
Novan, Inc.
Novartis AG
Promius Pharma, LLC
RXi Pharmaceuticals Corporation
Tamir Biotechnology, Inc.
Verrica Pharmaceuticals Inc.
Zydus Cadila Healthcare Limited
Skip to top


Trophos SA - Product Pipeline Review - 2014 US$ 1,125.00 Jan, 2014 · 37 pages

Ask Your Question

Warts - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: